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Naturally acquired immunity (NAI) to Plasmodium falciparum malaria is mainly mediated
by IgG antibodies but the subclasses, epitope targets and effector functions have not
been unequivocally defined. Dissecting the type and specificity of antibody responses
mediating NAI is a key step toward developing more effective vaccines to control the
disease. We investigated the role of IgG subclasses to malaria antigens in protection
against disease and the factors that affect their levels, including vaccination with
RTS,S/AS01E. We analyzed plasma and serum samples at baseline and 1 month after
primary vaccination with RTS,S or comparator in African children and infants participating
in a phase 3 trial in two sites of different malaria transmission intensity: Kintampo in
Ghana and Manhiça in Mozambique. We used quantitative suspension array technology
(qSAT) tomeasure IgG1−4 responses to 35P. falciparum pre-erythrocytic and blood stage
antigens. Our results show that the pattern of IgG response is predominantly IgG1 or
IgG3, with lower levels of IgG2 and IgG4. Age, site and RTS,S vaccination significantly
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affected antibody subclass levels to different antigens and susceptibility to clinical malaria.
Univariable and multivariable analysis showed associations with protection mainly for
cytophilic IgG3 levels to selected antigens, followed by IgG1 levels and, unexpectedly,
also with IgG4 levels, mainly to antigens that increased upon RTS,S vaccination such
as MSP5 and MSP1 block 2, among others. In contrast, IgG2 was associated with
malaria risk. Stratified analysis in RTS,S vaccinees pointed to novel associations of
IgG4 responses with immunity mainly involving pre-erythrocytic antigens upon RTS,S
vaccination. Multi-marker analysis revealed a significant contribution of IgG3 responses
to malaria protection and IgG2 responses to malaria risk. We propose that the pattern
of cytophilic and non-cytophilic IgG antibodies is antigen-dependent and more complex
than initially thought, and that mechanisms of both types of subclasses could be involved
in protection. Our data also suggests that RTS,S efficacy is significantly affected by NAI,
and indicates that RTS,S vaccination significantly alters NAI.
Keywords: Malaria, Plasmodium falciparum, antibody, IgG subclass, naturally acquired immunity, protection,
vaccine, children
INTRODUCTION
Malaria caused by Plasmodium falciparum is a significant health
problem particularly in children under 5 years old in sub-
Saharan Africa, with about 219 million cases and 435,000 deaths
worldwide (1). In areas of heavy and continuous transmission
of P. falciparum, naturally-acquired immunity (NAI) to malaria
is acquired with age and exposure (2). NAI is mediated by IgG
antibodies mainly to antigens of the parasite asexual blood stage
(BS) (2, 3) but the specific epitope targets, subclasses and effector
functions have not been unequivocally defined. Elucidating
these knowledge gaps is important for the development and
improvement of vaccines to control and eliminate malaria.
Despite the lack of a highly efficacious malaria vaccine, the most
advanced product, RTS,S/AS01, is due to start implementation
studies in 2019. RTS,S/AS01E has already undergone a phase 3
trial in Africa, where it showed partial protection with overall
vaccine efficacy of 25.9% in infants and 36.3% in children
(4). RTS,S is a self-assembling virus-like particle consisting of
a recombinant protein containing part of the central tandem
repeat from the P. falciparum circumsporozoite protein (CSP)
plus epitopes from the CSP carboxy-terminal, targeting the
sporozoite, and liver stages of infection, and fused to the S
surface antigen of hepatitis B (HBsAg) virus and coexpressed
with HBsAg alone. In the phase 3 trial, RTS,S was formulated
in the AS01E liposomal adjuvant containing monophosphoryl
lipid A and QS21 and was designed to induce strong anti-CSP
antibody and T helper 1 cell responses (4). Although NAI is
mainly directed against BS antigens, a natural response to CSP
also exists (5) and immunization with irradiated sporozoites
confers sterile immunity (6).
Sero-epidemiological studies usually measure total IgG, but
the specific subclass is less frequently studied. The relevance
of quantifying IgG subclasses relies on their different biological
properties. As a consequence, differential associations of each
subclass with protection may be masked when studied together.
IgG1 and IgG3 are considered to be protective antibodies
against Plasmodium spp. infection (7–11, 11–15). They are
known as the cytophilic subclasses due to their high affinity
for most of the Fc receptors on diverse immune cells and
their function in complement fixation and opsonization (16).
This gives them the ability to mediate protection against
malaria through complement-mediated lysis (17) and cell-
mediated mechanisms, such as opsonic phagocytosis (15, 18–
20) and antibody-dependent cellular inhibition (ADCI) (21).
IgG2 and IgG4 have been classically considered as non-protective
antibodies against malaria (6–8, 12, 20). In contrast to the
previous subclasses, IgG2 and IgG4 have low or no affinity
for complement, respectively, and are known as non-cytophilic,
because they poorly engage Fc receptors (16). Therefore their
main function is neutralization (16). However, IgG4 has high
affinity for the activating receptor FcγRI (22), which is expressed
on macrophages, monocytes, activated neutrophils, eosinophils
and mast cells and is regulated by exposure to cytokines (23).
In addition, IgG4 has the highest affinity compared to other
subclasses to the inhibitory receptor FcγRIIb (22), at moderate
levels present in B cells, macrophages and basophils (23). IgG2
and IgG4 are also suggested to have higher affinity for antigens
compared to IgG1 and IgG3. As a consequence, they might out-
compete the cytophilic subclasses, preventing or inhibiting cell
activation (24, 25).
However, not all reports are consistent with this classical
view of protective cytophilic and non-protective non-cytophilic
antibodies. For example, IgG2 may have cytophilic properties
in individuals carrying the H131 allele of the FcγRIIa receptor,
which can bind IgG2 (26). Further, IgG2 has been associated
with malaria protection (27), mostly in populations that carry the
H131 allele (28, 29). Interestingly, the H131 allele has decreased
binding for IgG4 compared to the other allele R131. In addition,
anti-CSP IgG4 showed a possible association with protection
in RTS,S/AS01 vaccinated subjects (30) and a human IgG4
monoclonal antibody against P. falciparum sporozoite inhibited
hepatocyte invasion by sporozoites in vitro (30). However, our
recent phase 3 trial studies with RTS,S/AS01E-induced anti-CSP
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antibodies showed that IgG4 to CSP was not associated with
protection, whereas IgG1 and IgG3 were (31).
Apart from naturally-acquired IgG responses, maternally
transferred antibodies are a source of immunity during the
first months of life, and they need to be taken into account
when including infants in field studies of malaria immunity,
particularly as baseline factors. IgG crosses the placenta, but the
subclasses show differences: IgG1 is preferentially transferred,
followed by IgG4, IgG3, and IgG2 (16, 32–34). Therefore, the
ability of each IgG subclass to cross the placenta might also
influence the susceptibility to Plasmodium spp in infants and
should be taken into account when analyzing IgG patterns in
individuals of this age.
We have previously developed and optimized assays (35, 36)
to measure IgG, IgG1−4 to large panels of diverse antigens with
different immunogenicities using the quantitative suspension
array technology (qSAT). In the context of the African pediatric
multicenter RTS,S/AS01E phase 3 trial for licensure (37, 38),
we previously analyzed the role of IgG, IgG1−4, and IgM to
RTS,S antigens in vaccine efficacy (31). We found that the
pattern of vaccine-induced IgG subclasses for CSP was key in
immunity, with IgG1 and IgG3 being protective and IgG2 and
IgG4 detrimental. Here, we aimed to better understand the
differential role that IgG1−4 subclass responses to P. falciparum
antigens considered as targets of NAI might have in protection
against clinical malaria disease in children who are naturally
exposed to the parasite and who receive a primary immunization
course with three doses of RTS,S/AS01E or a comparator vaccine.
To this end, we analyzed at two different time points the levels of
IgG subclasses to a range of RTS,S-unrelated antigens in African
children from two different malaria endemic areas, evaluating the
effect of age, site, and vaccination, and the association of those
antibody subclasses with protection against malaria.
MATERIALS AND METHODS
Study Design
This study was carried out in two of the seven sites included in the
multicenter immunology study MAL067, ancillary to the phase
3 randomized clinical trial MAL055 (NCT00866619): Kintampo
in Ghana (representative of moderate-high malaria transmission
intensity [MTI]) and Manhiça in Mozambique (representative
of low MTI) (39) to be able to compare the antibody responses
in relation to endemicity. These two sites were chosen due to
higher availability of sufficient numbers and volumes of samples
from both study visits and age cohorts. Subjects were followed
up by passive case detection (PCD) starting 14 days after sample
collection at month (M) 3, approximately 44 days after the
third dose (M2), for the subsequent 12 months, when they
were censored.
Children 5-17 months and infants 6–12 weeks at recruitment
with ≥150 µL plasma/serum samples available at M0 (baseline)
and M3 were selected. We included 129 RTS,S/AS01E—(46
infants and 33 children in Manhiça, 26 infants, and 24 children
in Kintampo) and 66 comparator—(23 infants and 15 children in
Manhiça, 14 infants, and 14 children in Kintampo) vaccinated
subjects from both sites (total n = 195). For the correlates
of malaria protection and risk analysis, 78 children and infants
were randomly selected from Kintampo, and 117 participants
were selected from Manhiça according to a prior case-control
study of cellular markers (40) and all were analyzed in a case-
control design.
The study protocol was approved by the Ethics Committees
from Spain, Mozambique and Ghana, and written informed
consent was obtained from parents or guardians.
Antibody Assays
qSATwas used tomeasure antibody responses to 35 P. falciparum
antigens (Supplementary Table 1) applying the xMAPTM
technology (Luminex Corp., Texas). Antigens were selected
on the basis of profiling BS immunity, but also for effect of
vaccination on PE immune responses to sporozoite (SSP2/TRAP
and CelTOS) and liver stages (LSA1). Although some of the BS
antigens have been characterized as markers of exposure,
such as AMA1 and MSP142 (Supplementary Table 1),
antigen selection was primarily directed toward prominent
targets of NAI, vaccine candidates or prior association with
protection in sero-epidemiological studies or animal models.
Additionally, several antigens were specifically included with
said characteristics and limited polymorphism (e.g., Rh2, Rh4,
Rh5, and EBA140). VAR2CSA, a pregnancy-specific variant of
P. falciparum erythrocyte membrane proteins, was included
as a representation of maternally-derived antibodies. qSAT
assays included bovine serum albumin (BSA) and glutathione S-
transferase (GST) coupled beads for background determination
and as a control for signal from non-specific binding of
P. falciparum GST fusion proteins, respectively. P. falciparum
proteins were covalently coupled directly to MagPlex beads and
blocked with BSA. qSAT assays were previously standardized
and optimized to control for sources of variability (35, 36, 41).
Briefly, antigen-coupled multiplex beads were mixed with 50 µL
of test sample, negative or positive control (42, 43), at multiple
dilutions (see Supplementary Materials). After incubation
and washing, biotinylated secondary antibodies were added.
Following streptavidin-R-phycoerythrin incubations, samples
were acquired with a Luminex 100/200 analyzer and antibody
levels measured as median fluorescence intensity (MFI). Data
pre-processing is detailed in Supplementary Materials.
Statistical Analysis
Comparisons of crude Ig levels across antigens and IgG
subclasses were done through boxplots with geometric means,
medians and interquartile ranges (IQR), by t-tests, and p-values
adjusted by the Benjamini-Hochberg approach (44) considering
all antigens together within each subclass. Analyses included
either all subjects or separately by visit and by vaccination, and
in some cases stratifying by site, by age, and by age within a site.
To evaluate factors affecting M3 Ig levels to all antigens, we
fitted first univariable and next multivariable linear regression
models (coefficient, 95% CI, adjusted p-values) using M3
antibody levels (log10 MFI) as an outcome and including the
following predictors: vaccination, sex, malaria transmission
season at M3, having clinical malaria episodes between M0 and
M3, and baseline variables like age (in weeks), antibody levels
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(log10 MFI), hemoglobin (Hb) concentration, weight-for-age Z
score (WAZ), and height-for-age Z score (HAZ). Models were
also fitted separately at pre-vaccination. Malaria transmission
season was defined as high between April-October for Kintampo,
and November-April for Manhiça; the remaining months were
defined as low transmission. The effect of baseline antibody
levels (resulting from prior parasite exposure in the child
and/or maternal transfer in the infants) was evaluated using the
same antigen/Ig as the outcome variable at M3. The purpose
of presenting the analysis of the antibodies at baseline (before
vaccination) is that our prior studies showed that they have a very
significant influence on the M3 antibody levels and subsequent
risk of clinical malaria (31). Linearity of the associations
with continuous covariates was evaluated through penalized
splines in generalized additive models (GAM); variables
were modeled as linear. A stepwise algorithm was used in
multivariable models.
Analysis of antibody correlates of protection was based
on a case-control design. The outcome was clinical malaria
detected by PCD defined by fever >37.5◦C with any parasitemia
(without a detection limit) in the 12 months after the start
of follow-up (M3 plus 14 days). Logistic regression models
(odds ratio [OR], 95% CI, adjusted p-values) were fitted
first univariable and next multivariable to obtain the effect
of different predictors in the odds of having malaria. Main
predictors included levels (log10MFI) of antibodies at M3, and
increment (log10-transformed) of antibody levels between M0
and M3. The impact of the other covariates (same as above)
on the association between antibody responses and malaria
risk/protection was also assessed. The linearity of the log10-
transformed antibody levels was evaluated when the outcome
was case-control.
Multivariable models were obtained through the stepwise
algorithm, R package MASS (45) and function stepAIC.
Both backwards and forward methods were combined to
obtain the model with the minimum akaike information
criterion (AIC). All potential variables were proposed in
the first step of the model, not only the ones significant
in univariable analysis. Correction for multiple testing was
done by Benjamini-Hochberg. In the above analyses, statistical
significance was defined at the level of p < 0.05, and trend up
to p= 0.1.
Finally, we performed multi-marker analysis by principal
component analysis (PCA) and Partial Least Squares
Discriminant Analysis (PLS-DA) using the R packages
FactoMineR (46) and DiscriMiner (47), respectively. For
the PCA analysis, used to reduce all antibody responses to non-
correlated variables that summarize the response, we included
the log10-transformed levels of all antigen-subclass pairs at M3
to generate the principal components. We selected the first
three principal components that best explained the variance
of the data and tested these components on the variables of
malaria, vaccination, age and site. For PLS-DA, the response
variable was clinical malaria and analysis was performed using
the log10-transformed levels of all antigen-subclass pairs at
M3. Then, we used the PLS-DA components to run logistic
regressions, including also the variables of age, site and vaccine
in a multivariable model. Finally, we calculated the AUC
performance using the prediction of malaria outcome obtained
with the PLS-DA.
FIGURE 1 | IgG subclass distribution to Plasmodium falciparum antigens. Representative examples from the following parasite antigens (Supplementary Table 1 for
more details) whose analysis of antibody subclass responses showed differential patterns: MSP142 (3D7 strain), AMA1 (3D7 strain), RH5, SSP2 (or TRAP), MSP5, and
MSP1 block 2 (3D7 strain).
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RESULTS
Baseline Characteristics
RTS,S and comparator vaccinees were similar with regards
to baseline characteristics (age, sex, weight, height, other
vaccinations, previous malaria, season, distance to health center,
Hb concentration) and most of them (93%) completed the 12-
month post-vaccination follow-up (31). The median time to
drop out from the study was 113 (range 21–276) days, and
was due mostly to early terminations due to loss to follow-up
(7 subjects) or migration (4 subjects). A total of 89 malaria
clinical events were recorded during the follow-up time: 60
in Kintampo (36 in RTS,S and 24 in comparators) and 29 in
Manhiça (18 in RTS,S and 11 in comparators). Thirty-five clinical
malaria events (39%) were registered in the children age cohort
(48% in Kintampo [n = 29], 21% in Manhiça [n = 6]), and
the remaining in the infant age cohort. Parasitemia of subjects
who had clinical malaria was comparable between RTS,S and
comparator vaccinees. The Kaplan Meier median follow-up time
was 365 days (IQR= 128 to 365).
Factors Affecting Levels of IgG Subclasses
to P. falciparum Antigens
We detected IgG responses to most malarial antigens with a
predominance of the IgG1 subclass, followed by IgG3, although
some antigens (MSP2, MSP1 block [bl] 2 constructs, except the
Well strain, and RH5) had similar levels of IgG1 and IgG3
(Figure 1 and Supplementary Figure 1). Levels of IgG2 were
lower than those of IgG1 or IgG3, while levels of IgG4 were
the lowest. The magnitude of responses at the study visits M0
and M3 (1 month post-vaccination) was differentially affected by
several factors.
Effect of RTS,S Vaccination
For IgG1, three different patterns of antibody response
to vaccine-unrelated antigens emerged at M3 upon RTS,S
immunization compared to M0 or with comparator vaccinees
(Figures 2, 3 and Supplementary Figure 2, multivariable
models): decrease in antibody levels, increase in levels, and no
change in levels. In multivariable models, RTS,S vaccination
decreased significantly IgG1 levels to MSP142 3D7, AMA1
FVO, and pTRAMP (Figure 3). In contrast, RTS,S vaccination
significantly increased IgG1 levels to DBLα, MSP1 bl2 (3D7,
Well, RO33, and Mad20 strains), MSP6, RH2 2030, EBA175
R3-5, MSP5, EBA140 R3-5, and RH4.2 (trend for MSP2 CH150
and RH5). The IgG1 levels to the rest of antigens were not
significantly affected by RTS,S vaccination. IgG3 antibody levels
to DBLα, SSP2, MSP5, and MSP1 bl2 (Well and RO33 strains)
were higher after RTS,S vaccination (trend for RH2 2030 and
RH4.2), but the rest of responses did not change. IgG2 levels to
EXP1 decreased after RTS,S vaccination while levels increased
for VAR2CSA DBL3-4 and MSP5. The levels of IgG4 did not
significantly change with vaccination except for MSP5 that were
increased as with the other subclasses. PCA analysis (Figure 4A)
showed that, globally, IgG subclass responses did not differ
significantly by vaccination.
Effect of Age
Comparing antibody profiles over time, IgG levels significantly
decreased from M0 to M3 for some antigens probably
reflecting the decay of maternal antibodies, while for others
there was a statistically significant increase and others did
not show differences (Supplementary Figure 3). Notably, for
most antigens, the increase was mainly observed in RTS,S
vaccinees, confirming the effect of vaccination described above.
In multivariable analysis, the effect of age group on baseline
levels of IgG1 and IgG3 had a mixed pattern. Levels against
11 of 35 antigens were significantly higher in infants than
children, while levels against 10 and 13 out of 35 antigens
were significantly higher in children than infants for IgG1
and IgG3, respectively (Figure 5). These latter antigens were
pTRAMP, RH1, MSP3 3C, CyRPA, CelTOS, RH4.9, and MSP5
for both subclasses, RH5, EBA140, MSP1 bl2 Well for IgG1,
and p41, RH2 b240, LSA1, DBLα, and SSP2 for IgG3. Levels
of IgG2 were generally lower in children than infants (12 out
of 35 antigens) or not different except for MSP5 and MSP2
bl2 Mad20, for which IgG2 levels were significantly higher in
children than infants (Figure 5). In contrast, IgG4 levels to
17 of 35 antigens were significantly higher in children than
infants, except for MSP142 3D7, EXP1, and MSP2 for which
levels were significantly lower in children. In multivariable
models adjusted by M0 IgG levels and vaccination, among other
variables, M3 IgG levels were generally higher in children than
infants or not significantly different, except for IgG1 to RH4.9
and IgG1 and IgG2 to VAR2CSA DBL3-4 that were lower
(Figure 3). These M0 and M3 results could be observed also
in univariable analyses (Supplementary Figure 4). The higher
baseline IgG1 and IgG3 levels against many antigens in infants
than children suggest maternally-transferred antibodies, whereas
IgG4 antibodies appeared to be poorly transferred and/or already
induced in the first months of life. Higher levels in children
than infants at M3 adjusting for baseline levels suggests higher
acquired responses in children than infants during the 3-month
period. Analysis of IgG responses by PCA at M3 (Figure 4B)
showed that infants clustered together while children were more
disperse. The variables that contributed the most to PC1 and
PC2 and contributed to segregate partially the responses that
corresponded to children and infants were, on one hand, IgG3 to
MSP142 3D7 and, on the other hand, IgG3 to MSP1 bl2 Mad20,
and IgG4 to RH2 b240, LSA1, CelTOS, SSP2, RH2 (2030), MSP1
bl2 Mad20, EBA140 R3-5, and RH4.2.
Effect of Site (MTI)
In general, antibody levels were higher in Kintampo (high
MTI) than in Manhiça (low MTI) for most antigens
(Supplementary Figure 5). At M0, antibody levels were
significantly higher in Kintampo than in Manhiça to most
antigens except for IgG2 to MSP1 bl2 Mad20 and IgG4 to MSP3
3C, RH2 b240, LSA1, MSP1 bl2 (PA17 and Mad20) CelTOS,
SSP2, and MSP5, which were significantly higher in Manhiça
than Kintampo (Figure 5 and Supplementary Figures 6, 7).
In contrast, at M3 a more mixed pattern was observed in
models adjusted by baseline levels and vaccination, among other
variables. Some responses did not significantly differ by site
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FIGURE 2 | IgG subclass distribution to Plasmodium falciparum antigens per visit and vaccination group. Representative examples. Adjusted p-values are shown in
parenthesis.
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FIGURE 3 | Heatmap of multivariable analysis of the effect of RTS,S/AS01E vaccination and demographic, clinical, and epidemiological variables on IgG subclass
levels to Plasmodium falciparum pre-erythrocytic and blood stage antigens at month 3 visit. Linear regression was performed with antibody levels (log10MFI) as
outcome and other covariates adjusted (in parenthesis the reference category). Color coded cells show the 10∧Beta of each predictor (columns) for each model
(rows). Only results with a significant (<0.05) p-value are shown. Antigen colors show the P. falciparum life cycle stage in which they are expressed: Pre-erythrocytic
(PE) antigens from sporozoite stage (light purple), PE from liver stage (dark purple), blood stage (BS) antigens from merozoite stage (orange), BS from trophozoite
stage (yellow).
(27/35 antigens for IgG1 and 30/35 antigens for IgG2), others
were higher in Manhiça than Kintampo (6/35 antigens for IgG1,
3/35 for IgG2, 15/35 for IgG3 and 19/35 for IgG4), and only
anti-MSP142 antibodies of all subclasses were lower in Manhiça
than Kintampo (Figure 3 and Supplementary Figures 6, 7).
Thus, children and infants in Kintampo had significantly higher
levels to all subclasses and antigens with the exception of
IgG4 against some antigens, which were significantly higher
in Manhiça, but Manhiça subjects had increased levels of the
other subclasses from M0 to M3 to similar or higher levels than
Kintampo subjects. Analysis by PCA at M3 (Figure 4C) showed
clustering of individuals by site, although there was some overlap
with age. Most infants from both sites clustered together whereas
PC2 discriminated children from each site (Figure 4D).
Effect of Other Variables
At baseline there were not very generalized or consistent
significant associations with antibody levels and the rest of
covariates in multivariable models (Figure 5). Hb concentrations
were negatively associated with IgG1, IgG2, and IgG3 levels to
some antigens but positively associated with IgG4 levels. For
WAZ there were generally significant positive associations while
for HAZ there were significant negative associations, markedly
for IgG4. Sex was not significantly associated with M0 levels
except for IgG3 to MSP1 bl2 RO33 andMad20 (females>males)
and VAR2CSA DBL1-2 (males > females). At M3, the strongest
and more consistent associations were that higher M0 antibody
levels and prior malaria episodes were significantly associated
with higher M3 antibody levels (Figure 3).
Antibody Correlates of Malaria Protection
Baseline antibody levels of most subclasses/antigens were
generally significantly higher in those subjects who had clinical
malaria during the 12-month follow up after M3 than in those
who did not (Figure 6 and Supplementary Figure 8). At M3,
IgG1, IgG2 and IgG3 antibodies were also higher in malaria
cases for some antigens whose levels decreased from M0 to M3
(e.g., AMA1, MSP142). Stratified by age, this was more significant
in children (Supplementary Figure 9). Stratified by site, these
differences were not detected (Supplementary Figure 10). In
contrast, M3 IgG1, IgG2, and IgG3 levels that increased after
RTS,S vaccination or to those antigens whose antibodies did
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FIGURE 4 | Principal Components Analysis (PCA) of the antibody responses at month 3 (M3). The plots of the distribution of individuals by type of vaccine received
(A), age (B), site (C), or site plus age (D) are shown. The first three principal components (Dim 1, Dim 2, and Dim 3) that explained the highest percentage of the
variance of the antibody responses at M3 (percentage in parenthesis) were chosen for representation. Representation of the 10 first variables (antigen-IgG subclass
pairs) that contributed to the principal components (B). Black dots represent infants (D).
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FIGURE 5 | Heatmap of multivariable analysis of the effect of RTS,S/AS01E vaccination and demographic, clinical, and epidemiological variables on IgG subclass
levels to Plasmodium falciparum pre-erythrocytic and blood stage antigens at baseline. Linear regression was performed with antibody levels (log10MFI) as outcome
and other covariates adjusted (in parenthesis the reference category). Color coded cells show the 10∧Beta of each predictor (columns) for each model (rows). Only
results with a significant (<0.05) p-value are shown. Antigen colors show the P. falciparum life cycle stage in which they are expressed: Pre-erythrocytic (PE) antigens
from sporozoite stage (light purple), PE from liver stage (dark purple), blood stage (BS) antigens from merozoite stage (orange), BS from trophozoite stage (yellow).
not decrease from M0 to M3, did not generally differ in
cases and controls (Figure 6 and Supplementary Figures 8–10).
IgG4 followed a different pattern; crude levels of antibodies to
pre-erythrocytic (PE) antigens SSP2, LSA1, and CelTOS and
to MSP1 bl2 constructs were higher in protected than non-
protected subjects, not only at M3 but also at M0 (Figure 6 and
Supplementary Figures 8). M3 IgG3 levels to these antigens had
a similar pattern but associations were weaker. This IgG4 pattern
was mainly observed in children (Supplementary Figure 9)
and in Manhiça (Supplementary Figure 10). Stratified by age
and site, M3 crude IgG4 (and IgG3) levels to the above
and additional antigens were lower in Manhiça children with
malaria after RTS,S vaccination than non-malaria controls,
while the opposite pattern was seen for comparator vaccinees
(Supplementary Figure 11), suggesting an interaction with
vaccination (evident in this particular group).
Analysis of the change in IgG1 and IgG3 levels from M0
to M3 revealed significantly higher increments in controls than
malaria cases to most of the antigens that had increased antibody
responses in RTS,S vaccinees, particularly MSP1 bl2 constructs
and MSP5 (Supplementary Figure 12A). Stratifying by age and
site, the association was mostly seen for children and Kintampo
(Supplementary Figure 12B).
In logistic regression models adjusted by vaccine, age, site and
M0, among other variables when relevant, M3 IgG1 to AMA1
and RH1, IgG2 to AMA1 3D7, RH1 and RH5, and IgG3 and
IgG4 to MSP2 FL CH150, were associated with increased malaria
risk (Figure 7). On the contrary, levels of M3 IgG3 to MSP1
bl2 3D7, PA17, and hybrid, VAR2CSA DBL1-2 and LSA1, and
IgG4 to MSP1 bl2 PA17 and SSP2, were associated with malaria
protection. Also, in multivariable logistic regression models, the
difference between M3 and M0 levels for IgG1 to MSP5, MSP6,
MSP1 bl2 Well and MSP2 FL Dd2, and IgG3 to VAR2CSA
DBL1-2 and MSP5, was associated with protection, while IgG1
to MSP1 bl2 Mad20 was associated with risk (Figure 7). In
stratified analysis including only RTS,S vaccinees, IgG3 and
IgG4 levels to the PE antigens LSA1, SSP2 and CelTOS and
MSP1 bl2 constructs were associated with protection. Among
covariates retained in multivariable models (Figure 7), RTS,S
vaccination, children cohort (mostly), Manhiça site (always), low
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FIGURE 6 | Association between month 3 IgG levels and malaria protection after RTS,S vaccination. Only representative examples are included. Adjusted p-values
are shown in parenthesis. M, Malaria, NM, No malaria.
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FIGURE 7 | Continued
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FIGURE 7 | Forest plots of multivariable analysis of the association between IgG subclass responses to Plasmodium falciparum pre-erythrocytic and blood stage
antigens, and malaria protection. Logistic regression models with antibody levels at month 3 (M3), or change in M3 and M0 levels (M3-M0), as predictors and clinical
malaria as outcome, adjusted by covariates that entered the models according to the minimum akaike information criterion (RTS,S vaccination, age cohort, site, M0
antibody levels, WAZ and prior malaria episodes, depending on the antigen/subclass). OR: Odds ratio with 95% confidence intervals (CI). OR with a CI below
(protection) or above (risk) 1 are represented by a colored circle. Associations with a CI below or above 1 (asterisks) in stratified analysis including only RTS,S
vaccinees: IgG3 to LSA1 at M3: OR = 0.13 (0.02;0.71), p = 0.03; IgG3 to MSP1 bl2 Mad20 at M3: OR = 0.01 (0;0.33), p = 0.02; IgG3 to MSP1 bl2 RO33 at M3:
OR = 0.33 (0.09;0.99), p = 0.056; IgG3 to SSP2 (TRAP) at M3-M0: OR = 0.23 (0.05;0.86), p = 0.04; IgG3 MSP1 bl2 RO33 at M3-M0: 0.47 (0.2;0.99), p = 0.053;
IgG4 LSA1 at M3: OR = 0.07 (0;0.65), p = 0.058; IgG4 to CelTOS at M3: OR = 0 (0;0.28), p = 0.03; IgG4 to MSP1 bl2 Mad20 at M3: OR = 0 (0;0.25), p = 0.055.
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FIGURE 8 | Principal Components Analysis (PCA) of the antibody responses at month 3 (M3). The plots of the distribution of individuals by age (A) and site (B) plus
malaria are shown. The first three principal components (Dim 1, Dim 2, and Dim 3) that explained the highest percentage of the variance of the antibody data at M3
(percentage in parenthesis) were chosen for representation. Black dots represent malaria cases.
baseline antibody levels and high WAZ (specially for IgG2),
were associated (statistically significantly or not) with less risk
of malaria. Sex, prior malaria episodes, season, HAZ or Hb
were not significantly contributors to the models, except for
previousmalaria that improved the IgG3model (M3 levels, RTS,S
vaccinees only) for MSP1 bl 2 constructs.
In PCA analysis atM3, simultaneous representation ofmalaria
cases by age and site (Figures 8A,B) showed that most malaria
cases overlapped with infants and Kintampo, respectively. This
is in agreement with the observation in multivariable logistic
regression models, where children and Manhiça were associated
with less risk of malaria.
PLS-DA atM3withmalaria as a response variable (Figure 9A)
identified three main components associated with malaria.
The IgG subclass responses that contributed more to these
components (the 10 responses with higher loadings in each
component) included IgG1 to MSP142 and MSP2; IgG2 to
AMA1, MSP2, RH5, MSP1 bl2 constructs, LSA1, VAR2CSA
DBL1-2, RH1; IgG3 to MSP2, pTRAMP, VAR2CSA DBL1-
2, CelTOS, RH4.9, MSP5, RH2 (2030), SSP2 and MSP1 bl2
constructs; and IgG4 to MSP1, VAR2CSA DBL1-2 and DBLα
(Figure 9B). In a multivariable logistic model including these
three PLS-DA components and adjusted by age, site and vaccine,
the PLS-DA components were independently associated with
malaria (component 1 [p < 0.001], component 2 [p = 0.01] and
component 3 [p < 0.001]), while age (p = 0.76), site (p = 0.29),
and vaccine (p = 0.57) were not. The predictive ability of the
model was very high (75 out of 79 malaria cases and 94 out of
96 controls correctly predicted) with an AUC of 0.964.
A summary of all results according to single-marker
(univariable and multivariable regression models) and multi-
marker (PLS-DA) analysis, is presented in Figure 10. This
shows the groups of antigens whose levels of antibodies at M3
and/or changes in levels from M0 to M3, were associated with
malaria protection (green) or risk (purple), for each IgG1−4
subclass response.
DISCUSSION
Our study found that malaria protective immunity is mostly
associated with the cytophilic subclasses IgG1 and IgG3 and,
in spite of the low levels, with IgG4, to certain PE and BS
P. falciparum antigens, whereas IgG2 responses were mostly
associated with malaria risk. As expected, IgG1 followed by
IgG3 were the predominant subclasses in most antigens, with
lower IgG2 and IgG4 levels. Consistent with previous reports,
Frontiers in Immunology | www.frontiersin.org 13 March 2019 | Volume 10 | Article 439
Dobaño et al. IgG Subclasses and Malaria Immunity
FIGURE 9 | Partial Least Squares Discriminant Analysis (PLS-DA) plots. (A) 3D scatter-plot with the three main PLS-DA components that best enable discrimination
between malaria cases (M) and non-malaria controls (NM) using antibody levels at month 3 (M3) (cumulative R2 = 0.37). (B) Loadings of antigen-subclass pairs with
the 10 highest absolute scores for each PLS-DA component at M3.
MSP1 bl2, MSP2, and RH5 predominantly induced IgG3, or
similarly high IgG3 and IgG1 levels, and we found that this
was also the case for DBLα (48–51). Each IgG subclass and
antigen pairs studied showed a different pattern, magnitude,
and association with malaria protection, with different factors
affecting the outcome. Despite this complexity, we found novel
and consistent results regarding determinants of the antibody
response and impact on malaria outcomes.
IgG1 and IgG3 were differently associated with malaria
protection, depending on the antigen specificity. IgG1 levels
to antigens that are considered markers of exposure (MSP142,
AMA1, EXP1, etc.) were higher in infants than children and in
malaria cases than controls. This could be explained by presence
of maternal antibodies, which are preferentially of the IgG1
subclass due to the differential placental transfer (16, 32, 33)—
as shown by VAR2CSA antibodies that should be transferred by
the mother- and/or a higher pre-exposure to the parasite in these
individuals. It has been previously established that a strong risk
factor for future malaria is having had malaria in the past (13)
which can be manifested by higher baseline levels of IgG1 to
these BS antigens (52). In contrast, change from M0 to M3 in
IgG1 levels to a different group of antigens (MSP5, MSP6, RH4.2,
MSP1 bl2, etc.) was associated with protective responses. In the
case of IgG3, levels of antibodies to SSP2, LSA1, and MSP1 bl2 at
M3 were associated with less malaria risk.
There are differences between IgG1 and IgG3 that might have
implications for protection and that could explain why they differ
in levels, even though they show similar antigen reactivity. In
terms of similarities, they both respond mainly to proteinaceous
antigens and are cytophilic. However, IgG3 has a shorter half-
life (7 days) compared to the other subclasses (21 days) (16, 25),
meaning that the presence of IgG3 could depend on a continuous
or repeated exposure to compensate for the shorter half-life,
although some IgG3 allotypes have also shown extended half-
lives. Therefore, malaria exposure may influence IgG subclass
balance, such that early in infection an IgG1 response may be
dominant, and for some antigens this may then evolve to IgG3.
In addition, it is suggested that IgG3 has lower antigen-affinity
than IgG1, but it activates complement more effectively and has
higher affinity to Fcγ receptors (16, 25), thus, when present, it is
probably more effective in mediating effector mechanisms.
We hypothesized that while cytophilic antibodies IgG1
and IgG3 would be associated with protection, non-cytophilic
antibodies IgG2 and IgG4 would be associated with risk,
as reported in other studies (7–11, 11–15, 53), although
some studies have found protective associations with IgG2
(54). Unexpectedly, IgG4 showed potential associations with
immunity despite presenting the lowest levels. In univariable
analysis we found that higher IgG4 levels to all PE antigens
and MSP1 bl2 constructs correlated with malaria protection.
Interestingly, these responses helped discriminate between
children fromManhiça and infants and children from Kintampo,
suggesting that these responses may be particularly acquired in
Mozambique. In multivariable analysis, higher IgG4 levels to the
PE antigens SSP2 and LSA1 and one of the MSP1 bl2 constructs
were associated with protection. Regarding IgG2, responses to
AMA1, RH1 (like IgG1) and RH5, positively correlated with
malaria risk. Consistently, in multi-marker analysis IgG2 to
AMA1, RH1, and RH5 were identified as significant variables
predicting malaria disease, in addition to MSP2 FL CH150,
LSA1, VAR2CSA DBL1-2, and MSP1 bl2 constructs. This is in
agreement with the notion that production of non-cytophilic
IgG2 elicited by natural exposure to the parasite is non-protective
against malaria (7–9, 13, 53). Consistent with this, we have
previously found that higher levels of IgG2 to CSP induced by
RTS,S vaccination are associated with malaria risk in the phase
3 trial (31). Interestingly, infants had higher IgG2 levels than
children (except for MSP5 and MSP1 bl2 Mad20) at baseline,
which is surprising because this subclass is considered to be the
least efficiently transferred during pregnancy (16, 32, 33). This
probably reflects very high maternal IgG2 levels, as shown for
VAR2CSA antibodies.
Cytophilic subclasses are well known for mediating protection
in malaria through their ability to fix complement (17) and
mediate opsonic phagocytosis (15, 18–20) and ADCI (21).
A previous observation that phagocytic activity was lower
in protected than non-protected subjects vaccinated with
RTS,S/AS01 (55) led to the discovery that the neutralizing and/or
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FIGURE 10 | Summary of associations between antibody responses and malaria protection. Purple represents association with malaria risk and green with protection.
inhibitory function of IgG4 to CSP is associated with reduced
phagocytic activity, linking IgG4 with a possible protective
function in RTS,S vaccinees (30). IgG4 has the highest affinity
to antigens compared to the other IgG subclasses, which could
result in the ability to out-compete IgG1 and IgG3 even at low
concentrations (24, 25) andmay explain the different associations
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with risk and protection. Thus, IgG4 would be protective by
blocking opsonic phagocytosis mediated by cytophilic subclasses,
which could be used by Plasmodium spp. as a means to shelter
in phagocytes and then evade the immune system (30). In
view of these results, we propose that this mechanism of IgG4
protection could apply to other non-vaccine related antigens and
that protection needs a delicate balance combining the cytophilic
activity elicited by IgG1 and IgG3 with the blocking activity of
IgG4. This balance can be affected by factors such as the target
antigen, age, MTI and RTS,S vaccination (56).
Unexpectedly, IgG1 and IgG3 levels to some antigens (DBLα,
EBA140 R3-5, EBA175 R3-5, MSP1 bl2 [3D7, Well, RO33, and
Mad20 strains], MSP5, MSP6, RH2 2030, RH4.2, and SSP2)
increased after RTS,S vaccination. In contrast, levels of IgG1
to exposure antigens (AMA1 and MSP142) decreased following
RTS,S immunization, suggesting that RTS,S vaccinees were less
exposed to the parasite due to vaccine efficacy. Importantly,
among the antigens to which antibodies were higher after RTS,S
vaccination, MSP1 bl2 Well, MSP2 FL Dd2, MSP5, and MSP6
showed higher levels in controls than in malaria cases and were
associated with protection in adjusted models for IgG1 and some
for IgG3, while IgG1 to AMA1 and RH1, which decreased or
did not change with RTS,S vaccination, were associated with
malaria risk. Similarly, higher M0 to M3 change of IgG3 levels
to MSP1 bl2 and MSP5, which were increased by RTS,S vaccine,
was observed in controls than malaria cases. In adjusted models,
IgG3 to MSP1 bl2, MSP5 (in addition to VAR2CSA DBL1-2,
which was not affected by RTS,S vaccine) were also associated
with protection at M3. In contrast to IgG1, stratified analysis
including only RTS,S vaccinees showed that IgG3 to PE antigens
LSA1 and SSP2 andMSP1 bl2, the latter two increased after RTS,S
vaccination, correlated with protection. For IgG3, associations
with malaria risk were only found for MSP2 FL CH150, which
was not affected by RTS,S vaccination. In multi-marker analysis
of M3 antibody levels, IgG1 levels to MSP142 and IgG1 and
IgG3 levels to MSP2 contributed significantly and positively to
the components associated with malaria, whereas IgG3 levels to
numerous antigens including VAR2CSA DBL1-2, MSP1 bl2 3D7,
MSP5 contributed to the components in an inverse relationship,
consistent with the malaria protective associations in previous
results. In addition, IgG3 to pTRAMP, CelTOS, RH4.9, SSP2, and
RH2 were also important variables in the components suggesting
a role in malaria protection. RTS,S vaccination also decreased the
levels of IgG2 to EXP1, another exposure antigen, but it increased
the levels of IgG2 to VAR2CSA DBL3-4 and IgG2 and IgG4 levels
to MSP5. However, these responses were not associated with
protection against malaria.
The observation that a vaccine that reduces exposure to the
parasite is associated with an increase in IgG1 or IgG3 levels
to certain antigens, and that this increase may be associated
with malaria protection, could be related to the fact that RTS,S
does not result in sterile immunity, particularly during the
course of primary vaccination; instead, it is a partially-effective
or “leaky” PE vaccine. To explain the differences in duration
of vaccine efficacy between two cohorts of diverse MTI in
the Mozambican phase 2b clinical trial (57), we hypothesized
that partial protection afforded by RTS,S/AS0 may stimulate
protective antibodies to certain malaria target antigens, through
a reduction of merozoite release from the liver, leading to
attenuated BS parasitaemia (58). Partially controlled infection
would result in subpatent low antigen doses that could elicit
enhanced IgG production to certain antigens, which would reflect
in accelerated acquisition of BS protective immunity (59). While
we could not observe this effect in a past study assessing IgG
responses to a different set of antigens 6 months after vaccination
(59, 60), IgG1 and IgG3 data obtained here would fit with this
hypothesis. Alternatively, the effect on antibody levels could be
due to antigen-specific immune stimulation provided by the
adjuvant. It appears unlikely that RTS,S would be inducing
antibodies to CSP that cross-react with other merozoite antigens.
In addition, IgG1 to LSA1 and SSP2 and IgG4 to CelTOS
and a trend for LSA1, were associated with protection in RTS,S
vaccinees in multivariable analyses. Multi-marker analysis also
revealed a significant contribution of IgG3 to pTRAMP, CelTOS,
and SSP2 (which were increased after RTS,S vaccination) to
protection. We wondered how RTS,S might benefit the response
to other PE antigens and a protective effect in RTS,S vaccinees.
We speculate that the anti-CSP antibodies induced by the vaccine
prevent the quick invasion of the hepatocytes (61), and this could
allow a longer exposure of the sporozoites to the immune system,
phagocytosis and antigen presentation to T cells, facilitating
the response to PE antigens, which could have a synergistic
effect with anti-CSP antibodies. When stratified by age and site
at M3, an interesting pattern appeared for IgG4 to these and
other antigens: children with malaria in the RTS,S group had
lower levels of IgG4 while children with malaria who received
the comparator vaccine had higher IgG4 levels. This suggests
that there might be an RTS,S effect in the association of IgG4
responses with protection.
Age and site also affected IgG4 responses, children showing
higher levels than infants, and Manhiça higher levels than
Kintampo. In general, levels for IgG subclasses (less evident
for IgG2) increased with age and IgG4 was not an exception.
In fact, a previous study showed that IgG4 levels to EBA175
increased with age (13). As for site, a lower MTI could favor
IgG4 rather than high MTI because it has been shown that anti-
inflammatory cytokines, such as IL-10, increase with decreasing
MTI (62). IL-10 is a key cytokine inducing IgG4, further relating
this subclass with anti-inflammatory, and immune regulation
effects (63). Nonetheless, we acknowledge that a bias by site
cannot be discarded as the design of the study had this limitation.
It included mostly malaria cases in Kintampo, and mostly no
malaria controls in Manhiça, most of whom were children and
the few cases were mostly infants.
Some antigens showed remarkable patterns in this study.
Particularly, the higher IgG1−4 levels to MSP5 after RTS,S
immunization and their association with protection (64, 65).
IgG1 to MSP1 bl2 constructs (66, 67) also increased post-
vaccination and were associated with protection. Both are
merozoite surface proteins and have been associated with
reduced malaria, but they also have distinct features. MSP5
is a highly conserved antigen, whose function is unknown
and is not essential for growth in vitro (68) although it has
never been reported to be absent in sequenced field strains. In
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contrast, MSP1 bl2 is a highly polymorphic region of the N-
terminal of this large protein which C-terminal end mediates the
initial steps of merozoite invasion (68). MSP5 mainly induces
IgG1 whereas MSP1 bl2 mainly elicits IgG3. An explanation
for this is given by the conservation theory, which says that
conserved antigens mainly elicit IgG1 whereas polymorphic
antigens tend to elicit IgG3 (69) although this is not a consistent
finding; for example, antibodies to the conserved regions of
EBA175, EBA140, EBA181, are mainly IgG3 (70). Another
explanation is that antibodies to structured regions or proteins
are IgG1-skewed and antibodies to disordered proteins or regions
are IgG3-skewed. Due to the peculiar pattern of naturally-
acquired antibody responses to MSP5 and MSP1 bl2 upon RTS,S
vaccination and their association with protection, their potential
role in the efficacy and duration of RTS,S vaccine immunity and
as adjunct or combination vaccines merit further study.
To conclude, we found that malaria protection was associated
with cytophilic IgG3 levels mostly, IgG1 levels and, unexpectedly,
with IgG4 responses to vaccine-unrelated antigens, specially
MSP5 and MSP1 bl2, but also PE proteins, particularly in
RTS,S vaccinees. These antigens are candidates to be included
in multivalent and multistage second-generation vaccines that
could attain higher efficacy than current products. In contrast,
IgG2 responses were associated with higher risk of malaria.
Our results highlight the need to assess subclass responses
to malaria antigens in addition to total IgG responses
since their levels and effector mechanisms are different,
with subsequent impact on malaria protection. Importantly,
the data of this study provides a better understanding
of the interaction between NAI and RTS,S/AS01E-induced
immunity. According to our results, NAI contributes to the
protection afforded by RTS,S and RTS,S vaccination affects
the acquisition of NAI against PE and BS antigens, increasing
responses to those that are primarily associated with protection
against malaria.
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